Citations

Mayo Clinic

Showing 10 of 108599 citations.

Skull Deformation Has No Impact on the Variation of Brain Intracranial Pressure
Rezaei, Asghar, Sarvghad‐Moghaddam, Hesam , Eslaminejad, Ashkan, Ziejewski, Mariusz, Karami, G.

Volume 3: Biomedical and Biotechnology Engineering | February 11, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/imece2016-67518 Get It

Skull deformation and vibration has been hypothesized to be an injury mechanism when the human head undergoes an impact scenario. The extent that skull deformation may increase the risk of traumatic brain injury, however, is not well understood. This computational study explains whether skull deformation has any impact on the variation of intracranial pressure (ICP). To this end, a finite element head model including major anatomical components of the human head was employed. The head model has been validated against ICP variations on the brain. The impact simulations were carried out using a rigid cylindrical impactor. The scenarios were frontal impacts with the impactor hitting the forehead of the head model at two impact severity levels. In order to examine the effect of skull elasticity on the stress wave propagation inside the cranium under an external applied force, the skull was also taken as a rigid body with the same density as the elastic one, and the result were compared with those obtained with the deformable skull. For the two cases, the variation of ICPs at the coup and countercoup sites were recorded and compared. The results of the study showed that, for the case studies presented here, the deformation of skull didn’t increase the level of ICP inside the brain. It was concluded that the skull rapid body motion might be responsible for brain injuries.
Mechanical Response of the Brain Under Blast: The Effect of Blast Direction and the Head Protection
Sarvghad‐Moghaddam, Hesam , Rezaei, Asghar, Eslaminejad, Ashkan, Ziejewski, Mariusz, Karami, G.

Volume 3: Biomedical and Biotechnology Engineering | February 11, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/imece2016-67513 Get It

Blast-induced traumatic brain injury (bTBI), is defined as a type of acquired brain injury that occurs upon the interaction of the human head with blast-generated high-pressure shockwaves. Lack of experimental studies due to moral issues, have motivated the researchers to employ computational methods to study the bTBI mechanisms. Accordingly, a nonlinear finite element (FE) analysis was employed to study the interaction of both unprotected and protected head models with explosion pressure waves. The head was exposed to the incoming shockwaves from front, back, and side directions. The main goal was to examine the effects of head protection tools and the direction of blast waves on the tissue and kinematical responses of the brain. Generation, propagation, and interactions of blast waves with the head were modeled using an arbitrary Lagrangian-Eulerian (ALE) method and a fluid-structure interaction (FSI) coupling algorithm. The FE simulations were performed using Ls-Dyna, a transient, nonlinear FE code. Side blast predicted the highest mechanical responses for the brain. Moreover, the protection assemblies showed to significantly alter the blast flow mechanics. Use of faceshield was also observed to be highly effective in the front blast due to hindering of shockwaves.
Letter to the Editor: Richerand et al, J Pediatr Orthop. 2016;36:530–533
Su, Alvin W.Y. , Milbrandt, Todd A. , Stans, Anthony A. , McIntosh, Amy L. , Scheuler, Beth A., Larson, A. Noelle

Journal of Pediatric Orthopaedics | February 11, 2017 | Volume: 38 | Issue: 1 | Pages: e26-e26

10.1097/bpo.0000000000000938 | PMID 28141686 Get It

What Are the Indications for Spinal Fusion Surgery in Scheuermann Kyphosis?
Polly, David W. , Ledonio, Charles Gerald T., Diamond, Beverly, Labelle, Hubert , Sucato, Daniel J. , Hresko, M. Timothy , Emans, John B. , Vitale, Michael G. , Erickson, Mark A. , Larson, A. Noelle , Polly, David

Journal of Pediatric Orthopaedics | February 11, 2017 | Volume: 39 | Issue: 5 | Pages: 217-221

10.1097/bpo.0000000000000931 | PMID 30969249 Get It

Background: Surgical indications for Scheuermann kyphosis are variable. We sought to evaluate the characteristics of patients undergoing operative versus nonoperative treatment of Scheuermann kyphosis to better understand current practices and the factors which contribute to the decision for surgical management. Methods: Multicenter prospective cohort study. We evaluated consecutive patients presenting with Scheuermann kyphosis. Patients underwent either surgical or nonoperative management according to surgeon and patient discretion. Preoperative patient-reported outcome measures (Scoliosis Research Society and Spinal Appearance Questionnaire scores), demographics, and radiographic characteristics were assessed. Results: Overall, 150 patients with Scheuermann kyphosis were enrolled, with 77 choosing nonoperative treatment and 73 treated operatively. Compared with the nonoperative cohort, patients treated operatively were older (16.3±2.0 vs. 15.1±2.2, P=0.0004), and had higher body mass index (26.3±7.2 vs. 22.7±6.5, P=0.003), had greater T2-T12 kyphosis (71±14 degrees vs. 61±12 degrees, P<0.001), increased pelvic incidence (46 vs. 41 degrees, P=0.03) and pelvic tilt (10 vs. 3 degrees, P=0.03). There was no detected difference in maximal sagittal Cobb angle in the operative versus nonoperative patients (73±11 vs. 70±12 degrees, P=0.11). Functionally, the operative patients had worse Scoliosis Research Society pain scores (3.7±0.9 vs. 4.1±0.7, P=0.0027) and appearance scores (2.9±0.7 vs. 3.4±0.8, P <0.0001). Conclusions: Patients undergoing surgical management of Scheuermann disease were more likely to have large body mass index and worse pain scores. Other factors beyond radiographic measurement likely contribute to the decision for surgical management of Scheuermann kyphosis. Level of Evidence: Level II.
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS‐T): 2017 update on diagnosis, risk‐stratification, and management
Patnaik, Mrinal M. , Tefferi, Ayalew

American Journal of Hematology | February 11, 2017 | Volume: 92 | Issue: 3 | Pages: 297-310

10.1002/ajh.24637 | PMID 28188970 Get It

AbstractDisease OverviewRing sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic syndromes with RS (MDS‐RS) and RARS with thrombocytosis (RARS‐T); now called myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T).DiagnosisMDS‐RS is a lower risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and ≥15% BM RS (≥5% in the presence of SF3B1 mutations). MDS/MPN‐RS‐T, now a formal entity in the MDS/MPN overlap syndromes, has diagnostic features of MDS‐RS‐SLD, along with a platelet count ≥ 450 × 10(9)/L and large atypical megakaryocytes (similar to BCR‐ABL1 negative MPN).Mutations and KaryotypeMutations in SF3B1 are seen in ≥80% of patients with MDS‐RS‐SLD and MDS/MPN‐RS‐T, and strongly correlate with the presence of BM RS; MDS/MPN‐RS‐T patients also demonstrate JAK2V617F, ASXL1, DNMT3A, SETBP1, and TET2 mutations; with ASXL1/SETBP1 mutations adversely impacting survival. Cytogenetic abnormalities are uncommon in both diseases.Risk stratificationMost patients with MDS‐RS‐SLD are stratified into lower risk groups by the revised‐International Prognostic Scoring System (R‐IPSS). Disease outcome in MDS/MPN‐RS‐T is better than that of MDS‐RS‐SLD, but worse than that of essential thrombocythemia. Both diseases have a low risk of leukemicTreatmentAnemia and iron overload are complications seen in both and are managed similar to lower risk MDS and MPN. Aspirin therapy is reasonable in MDS/MPN‐RS‐T, especially in the presence of JAK2V617F, but the value of platelet‐lowering drugs is uncertain.
Prophylactic Plasma Transfusion Is Not Associated With Decreased Red Blood Cell Requirements in Critically Ill Patients
Warner, Matthew A. , Jenkins, Gregory D. , Kor, Daryl J. , Chandran, Arun Kumar , Warner, Matthew A

Anesthesia & Analgesia | February 11, 2017 | Volume: 124 | Issue: 5 | Pages: 1636-1643

10.1213/ane.0000000000001730 | PMID 28181937 Get It

BACKGROUND: Critically ill patients frequently receive plasma transfusion under the assumptions that abnormal coagulation test results confer increased risk of bleeding and that plasma transfusion will decrease this risk. However, the effect of prophylactic plasma transfusion remains poorly understood. The objective of this study was to determine the relationship between prophylactic plasma transfusion and bleeding complications in critically ill patients. METHODS: This is a retrospective cohort study of adults admitted to the intensive care unit (ICU) at a single academic institution between January 1, 2009 and December 31, 2013. Inclusion criteria included age ≥18 years and an international normalized ratio measured during ICU admission. Multivariable propensity-matched analyses were used to evaluate associations between prophylactic plasma transfusion and outcomes of interest with a primary outcome of red blood cell transfusion in the ensuing 24 hours and secondary outcomes of hospital- and ICU-free days and mortality within 30 days of ICU discharge. RESULTS: A total of 27,561 patients were included in the investigation with 2472 (9.0%) receiving plasma therapy and 1105 (44.7%) for which plasma transfusion was prophylactic in nature. In multivariable propensity-matched analyses, patients receiving plasma had higher rates of red blood cell transfusion (odds ratio: 4.3 [95% confidence interval: 3.3–5.7], P < .001) and fewer hospital-free days (estimated % increase: −11.0% [95% confidence interval: −11.4, −10.6%], P < .001). There were no significant differences in ICU-free days or mortality. These findings appeared robust, persisting in multiple predefined sensitivity analyses. CONCLUSIONS: Prophylactic administration of plasma in the critically ill was not associated with improved clinical outcomes. Further investigation examining the utility of plasma transfusion in this population is warranted.
Addressing Physician Burnout
Shanafelt, Tait D. , Dyrbye, Liselotte N. , West, Colin P. , Dyrbye, Lotte N

JAMA | February 11, 2017 | Volume: 317 | Issue: 9 | Pages: 901

10.1001/jama.2017.0076 | PMID 28196201 Get It

The Non‐Inferiority Margins in Migraine Research ( NIMM ) Survey
Orr, Serena L. , Ramsay, Tim , Christie, Suzanne, Gladstone, Jonathan P., Dowlatshahi, Dar , Dodick, David, Dodick, David W.

Headache: The Journal of Head and Face Pain | February 11, 2017 | Volume: 57 | Issue: 5 | Pages: 729-736

10.1111/head.13048 | PMID 28188613 Get It

Objectives To survey experts in Headache Medicine on their opinions regarding appropriate non‐inferiority margins for outcomes commonly used in migraine research. Methods Members of the American Headache Society and the Canadian Headache Society were invited to participate in the Non‐Inferiority Margins in Migraine Research (NIMM) survey. Adult and child neurologists with expertise in Headache Medicine were eligible to participate. The survey had a multiple choice format and comprised questions on respondent characteristics, eligibility, as well as expert opinion on non‐inferiority margins for outcomes commonly used in trials of both prophylactic and acute interventions for migraine. Results Ninety‐nine eligible respondents completed the survey. Most respondents were adult neurologists (84.9%) and 74% reported practicing in the USA. The following were the most commonly selected non‐inferiority margins: (1) change in monthly migraine attacks comparing baseline to the treatment period: 1 attack (39.4% selecting), (2) change in monthly migraine days comparing baseline to the treatment period: 1 day (44.4%), (3) change in average migraine intensity on a 4‐point scale comparing baseline to the treatment period: 1.0 (31.3%), (4) percentage of participants who are pain‐free 2 hours after the intervention: 5% (41.4%), (5) percentage of participants who have a migraine recurrence within 48 hours of treatment: 5% (42.4%), and (6) percentage of participants with sustained pain freedom: 5% (42.4%). Conclusions The results of the NIMM survey describe the opinions of a group of experts on appropriate non‐inferiority margins for outcomes commonly used in migraine clinical trials. There was significant variability in responses and lack of consensus on the choice of non‐inferiority margins. The survey did not incorporate the patient perspective and was not validated prior to distribution. Further work in this area is required in order to explore how to incorporate clinical considerations into the selection of non‐inferiority margins for migraine research.
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
Wang, Xiaofei , Wang, Xiaoyi , Hodgson, Lydia, George, Stephen L., Foster, Nate R., Ganti, Apar Kishor, Stinchcombe, T., Crawford, Jeffrey, Kratzke, Robert A. , Adjei, Alex A. , Kindler, Hedy L., Pang, Herbert , George, Stephen L. , Ganti, Apar Kishor , Hodgson, Lydia, Sargent, Daniel J. , Stinchcombe, Thomas E. , Crawford, Jeffrey , Kindler, Hedy L. , Vokes, Everett E. , Ganti, Apar K

The Oncologist | February 11, 2017 | Volume: 22 | Issue: 2 | Pages: 189-198

10.1634/theoncologist.2016-0121 | PMID 28188257 Get It

Abstract Purpose The aim of this study was to investigate whether progression-free survival (PFS) can be considered a surrogate endpoint for overall survival (OS) in malignant mesothelioma. Materials and Methods Individual data were collected from 15 Cancer and Leukemia Group B (615 patients) and 2 North Central Cancer Treatment Group (101 patients) phase II trials. The effects of 5 risk factors for OS and PFS, including age, histology, performance status (PS), white blood cell count, and European Organisation for Research and Treatment of Cancer (EORTC) risk score, were used in the analysis. Individual-level surrogacy was assessed by Kendall’s tau through a Clayton bivariate Copula survival (CBCS) model. Summary-level surrogacy was evaluated via the association between logarithms of the hazard ratio (log HR)—log HROS and log HRPFS—measured in R2 from a weighted least-square (WLS) regression model and the CBCS model. Results The median PFS for all patients was 3.0 months (95% confidence interval [CI], 2.8–3.5 months) and the median OS was 7.2 months (95% CI, 6.5–8.0 months). Moderate correlations between PFS and OS were observed across all risk factors at the individual level, with Kendall’s tau ranging from 0.46 to 0.47. The summary-level surrogacy varied among risk factors. The Copula R2 ranged from 0.51 for PS to 0.78 for histology. The WLS R2 ranged from 0.26 for EORTC and PS to 0.67 for age. Conclusions The analyses demonstrated low to moderate individual-level surrogacy between PFS and OS. At the summary level, the surrogacy between PFS and OS varied significantly across different risk factors. With a short postprogression survival and a moderate correlation between PFS and OS, there is no evidence that PFS is a valid surrogate endpoint for OS in malignant mesothelioma.
Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates
Kim, Sang Gyune , Larson, Joseph J. , Lee, Ji Sung , Therneau, Terry M. , Kim, W. Ray

Liver Transplantation | February 10, 2017 | Volume: 23 | Issue: 6 | Pages: 733-740

10.1002/lt.24744 | PMID 28187503 Get It

Nonselective beta‐blockers (NSBBs) have played an important role in the prevention of portal hypertensive bleeding in patients with cirrhosis. However, recent studies have suggested that NSBBs may be harmful in some patients with end‐stage liver disease. The purpose of this article is to evaluate the association between use of NSBB and the incidence of acute kidney injury (AKI). We conducted a nested case‐control study in a cohort of liver transplant wait‐list registrants. Each patient with AKI was matched to a control by the Model for End‐Stage Liver Disease–Na score, age, serum creatinine, and follow‐up duration. Out of a total of 2361 wait‐list registrants, 205 patients developed AKI after a median follow‐up duration of 18.2 months. When compared with matched controls, ascites (79.0% versus 51.7%) and non‐Caucasian race (16.6% versus 7.8%) were more common among the cases. The frequency of NSBB use was higher among the cases than controls, albeit insignificantly (45.9% versus 37.1%; P = 0.08). In multivariate analyses, the impact of nonselective beta blockade on the development of AKI was dependent on the presence of ascites: nonselective beta blockade in patients with ascites significantly increased the risk of AKI (hazard ratio [HR], 3.31; 95% confidence interval [CI], 1.57‐6.95), whereas in patients without ascites, NSBB use reduced it (HR, 0.19; 95% CI, 0.06‐0.60). Potential benefits and harms of a NSBB in terms of AKI depend on the presence of ascites in liver transplant candidates. NSBB therapy in patients with cirrhosis may need to be individualized. Liver Transplantation 23 733–740 2017 AASLD.